Morphosys said it has agreed to a three-year extension of its ongoing research partnership with Japanese pharma firm Shionogi.
The agreement covers Shionogi's use of Morphosys' HuCal antibody platform for drug development research in exchange for annual user fees. Further financial details were not disclosed.
The project will be run on Morphosys' end by its AbD Serotec unit. Shionogi will have the right to use the company's HuCAL Platinum antibody library for research purposes at one of its research sites.
AbD Serotec uses its HuCAL – or Human Combinatorial Antibody Library – platform to generate monoclonal antibodies for research and diagnostic applications. The platform consists of a collection of several billion distinct fully human antibodies that, according to the company's website, allows for the rapid selection of antibodies with high affinity and specificity.
Morphosys and Shionogi first signed a license agreement for the use of the HuCAL platform in September 2005.